SPR Oncocare Private Limited

SPR Oncocare Private Limited is a private company incorporated on July 22, 2011, under the Corporate Identification Number (CIN) U51909KA2011PTC059691. The company is registered with the Registrar of Companies in Bangalore, Karnataka, India. Its authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. The registered office is located at No 12/1, 100 Feet Varthula Road, Anjaneya Nagar, Kathriguppe, Bangalore, Karnataka, 560085.

SPR Oncocare specializes in the wholesale trade of pharmaceutical products, focusing on anti-cancer formulations and herbal extracts. The company's product portfolio includes items such as Gefitinib Tablets, Lenvatinib Capsules, Vandetanib Tablets, and various herbal extracts like Ashwagandha and Curcumin.

Specific details regarding SPR Oncocare's manufacturing facilities are not publicly disclosed. The company is primarily engaged in trading, distributing, and outsourcing pharmaceutical products, with a specialization in new molecules and anti-cancer formulations.

The company's board of directors includes:

• Rajashri Prasad
• Kaliyur Nagappa Shiva Prasad
• Mangalagowri Nag
• Prakruthi Prasad

The role of Chief Executive Officer (CEO) or Managing Director (MD) is not explicitly mentioned in the available sources. The company's email contact is [email protected].

SPR Oncocare's export activities are primarily focused on the advanced oncology therapeutic category, with a total export value of $78,000 USD across 11 shipments. The top three exported products are:

• Cetuximab: $38,000 USD (Rank #4, 4.5% market share)
• Pembrolizumab: $27,000 USD (Rank #12, 1.4% market share)
• Olaparib: $14,000 USD (Rank #8, 1.5% market share)

These figures indicate a concentrated portfolio, with the top three products accounting for 100% of the company's export value.

SPR Oncocare has expressed interest in exporting to various countries, including Anguilla, Austria, Barbados, Belgium, Canada, China, Hong Kong S.A.R., Hungary, United Kingdom, and the United States. This suggests a strategic focus on both developed and emerging markets. (sproncocareprivateli.linker.store)

The company's export strategy appears to be diversified across multiple international markets, reducing concentration risk. However, the heavy reliance on a limited number of products may expose the company to market fluctuations affecting these specific drugs.

There is no publicly available information regarding SPR Oncocare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on trading and outsourcing suggests that it may not have direct FDA approvals for its products.

Specific details about SPR Oncocare's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available.

Information regarding SPR Oncocare's compliance with the Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) is not publicly disclosed.

There are no publicly available records of Form 483 observations, warning letters, or import alerts associated with SPR Oncocare.

SPR Oncocare operates in a competitive market, with competitors including AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. The company's focus on anti-cancer formulations and herbal extracts positions it in a niche segment, potentially reducing direct competition.

SPR Oncocare's specialization in new molecules and anti-cancer formulations, along with its engagement in contract manufacturing and trading, distinguishes it from competitors. The company's interest in exporting to a diverse set of countries indicates a proactive approach to market expansion.

SPR Oncocare's current strategic direction appears to be focused on trading, distributing, and outsourcing pharmaceutical products, with an emphasis on anti-cancer formulations and herbal extracts. The company's future outlook may involve expanding its product portfolio and enhancing its presence in both developed and emerging markets.

SPR Oncocare's track record in exporting pharmaceutical products, particularly in the oncology segment, indicates a level of reliability. However, the concentration of its export value in a few products suggests potential risks associated with market fluctuations affecting these specific drugs.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website.

• WHO-GMP: Ensure that the manufacturing facilities comply with World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website.

• EU GMP: Check for compliance with European Union Good Manufacturing Practices. Verification can be done through the European Medicines Agency's official website.

• ISO Certification: Verify that the company holds relevant ISO certifications for quality management systems. Verification can be done through the International Organization for Standardization's official website.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm that the products have the necessary approvals from relevant regulatory bodies.

• Assess Manufacturing Compliance: Ensure that manufacturing facilities adhere to international quality standards.

• Evaluate Financial Stability: Review the company's financial statements to assess its financial health.

• Check Export History: Assess the company's track record in exporting to ensure reliability.

• Monitor for Red Flags: Be vigilant for any signs of non-compliance or regulatory issues.

By following this checklist, importers can make informed decisions when considering SPR Oncocare as a supplier.